Lilly claimed it experienced initially launched Mounjaro in the united kingdom in a cost 'drastically down below the eu ordinary to stop delays in NHS availability' but this will have to now change 'to make certain truthful global contributions to the cost of innovation' 潛在風險：快速減重可能導致肌肉流失、骨質疏鬆等問題